• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CooperVision Partners with Canadian Olympic Speed Skater Valérie Maltais on Her Continued Pursuit of Excellence on the World Stage

    4/20/26 9:00:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care
    Get the next $COO alert in real time by email

    RICHMOND HILL, ON, April 16, 2026 /CNW/ - CooperVision Canada is proud to announce a new partnership with Valérie Maltais, one of Canada's most decorated Olympic speed skaters, as she continues to pursue excellence both on the ice and in her academic studies. As she trains toward the next major international competitions, Maltais relies on MyDay Energys® contact lenses, which deliver premium optics shown to improve vision and comfort*1,2.

    CooperVision Partners with Canadian Olympic Speed Skater Valérie Maltais (CNW Group/CooperVision Canada)

    Maltais' career is defined by speed, strategy, and precision. A five‑time Olympian and multi‑medalist, she competes in an environment where the smallest visual detail can determine the outcome of a race. Reliable, consistent vision is a competitive requirement—not a luxury.

    Balancing this with her academic work, completed largely through online courses, Maltais experiences the same digital‑device challenges facing millions of Canadians. MyDay Energys® helps support this demanding dual lifestyle.

    "I put my lenses on in the morning. I feel that my eyes are fresh, my vision is simply clear. I can go and do my training either on the ice, in the gym or on the bike." said Valérie Maltais. "This is my job as an athlete, I need to focus on my performances and getting ready. I'm also a student and most of my classes are online. I can focus on my schoolwork, looking at a screen and not feeling that my eyes are dry or my eyes are tired1. I would definitely recommend MyDay Energys® because for me it was just a positive experience."

    MyDay Energys® is made of a naturally wettable material with no need for surface treatments or coatings to help provide unsurpassed comfort. DigitalBoostTM technology may help ease eye muscle stress, resulting in better vision, less eye strain, and more comfortable eyes#‡2,3.

    "At CooperVision, our mission is to help people see better every day," said Kristine Churchward, Head of Marketing, CooperVision Canada. "Valérie's journey as both an elite athlete and committed student mirrors the varied visual demands many Canadians face. We're proud to support her with MyDay Energys®, a lens designed for the demands of modern, high‑performance lives."

    Through this partnership, CooperVision and Maltais will collaborate on initiatives that illuminate the critical role of vision in enabling active, modern lifestyles—whether in high‑performance sport, academic environments, or daily digital demands. Together, they aim to inspire Canadians to prioritize their eye health so they can pursue every ambition with clarity and confidence.

    CooperVision Canada is honoured to champion athletes like Valérie Maltais, whose pursuit of excellence mirrors our commitment to delivering vision solutions that elevate performance and enrich everyday life.

    *Compared to MyDay® sphere.

    #Compared to MyDay®/Biofinity

    ‡Based on a statistically significant difference of the mean change in Accommodative Microfluctuations and when compared to a lens without DigitalBoost/Digital Zone Optics® after reading on an iPhone 5 for 20 minutes held at a distance of 25 cm. Study conducted with Biofinity Energys® and sphere.

    1.CVI data on file, 2024. 2.CVI data on file 2018. Prospective, multi-center (5 US sites), open label, bilateral wear, one week dispensing study with MyDay and MyDay Energys. N=77 habitual soft CL wearers. 3. Kajita M et al. Changes in accommodative micro-fluctuations after wearing contact lenses of different optical designs. CLAE 2020; 43(5): 493-496.

    About CooperVision

    CooperVision, a division of CooperCompanies (NASDAQ:COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

    About CooperCompanies

    CooperCompanies (NASDAQ:COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women's health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.

    CooperVision (CNW Group/CooperVision Canada)

    SOURCE CooperVision Canada

    Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2026/20/c3736.html

    Get the next $COO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COO

    DatePrice TargetRatingAnalyst
    3/4/2026$85.00Buy → Neutral
    Rothschild & Co Redburn
    2/3/2026$100.00 → $99.00Buy
    Needham
    11/13/2025$72.00Overweight → Equal Weight
    Wells Fargo
    10/13/2025$85.00Overweight
    Barclays
    10/1/2025$64.00Sell
    Goldman
    8/28/2025$72.00Buy → Neutral
    Citigroup
    7/22/2025$92.00Neutral → Outperform
    BNP Paribas Exane
    6/17/2025$94.00Hold → Buy
    Needham
    More analyst ratings

    $COO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CooperCompanies Announces Second Quarter 2026 Results

    SAN RAMON, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2026. Second quarter 2026 revenue of $1.082 billion, up 8%, or up 5% organically, from last year's second quarter.Second quarter 2026 GAAP diluted earnings per share (EPS) of $(0.40), down $0.84 from last year's second quarter driven by a litigation-related charge to resolve outstanding claims associated with a December 2023 voluntary product recall at CooperSurgical.Second quarter 2026 Non-GAAP diluted EPS of $1.21, up $0.25 or 26% from last year's second quarter. See "Reconciliation of

    6/4/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperVision Names Muru Annamalai as President, Asia-Pacific

    Experienced Global Healthcare Leader to Guide Growth Across the RegionSINGAPORE, May 29, 2026 /PRNewswire/ -- CooperVision has named Muru Annamalai as President, Asia-Pacific, effective June 1, 2026. He brings more than two decades of global leadership experience across the pharmaceutical and healthcare sectors, with extensive expertise leading commercial organizations and driving growth across Asia-Pacific, Latin America, and other global markets. His appointment reflects CooperVision's broader investment in guiding the company's next phase of growth across one of its most dynamic and strategically important regions.

    5/29/26 8:05:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Appoints Paul Keel to its Board of Directors

    SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board. "We are delighted to welcome Paul to our Board as a new Director," said Colleen Jay, Chair of the Board of CooperCompanies. "His experience as a CEO in the medical device sector, along with a successful track record of leading complex global operations, will be a significant asset as Cooper continues to execute its strategy and create long-term value for patient

    5/4/26 4:15:00 PM ET
    $COO
    $NVST
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments

    $COO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rosebrough Walter M Jr

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    4/21/26 5:45:31 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Weiss Robert S

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    4/6/26 5:16:40 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Rivas Maria

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    4/6/26 5:16:25 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    SEC Filings

    View All

    $COO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $COO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 8-K filed by The Cooper Companies Inc.

    8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

    6/4/26 4:27:28 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SD filed by The Cooper Companies Inc.

    SD - COOPER COMPANIES, INC. (0000711404) (Filer)

    5/29/26 4:26:32 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    The Cooper Companies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

    5/4/26 4:30:44 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Cooper downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Cooper from Buy to Neutral and set a new price target of $85.00

    3/4/26 8:35:56 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Needham reiterated coverage on Cooper with a new price target

    Needham reiterated coverage of Cooper with a rating of Buy and set a new price target of $99.00 from $100.00 previously

    2/3/26 7:02:57 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Cooper downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Cooper from Overweight to Equal Weight and set a new price target of $72.00

    11/13/25 8:26:09 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Lucchese Cynthia L bought $149,963 worth of shares (1,784 units at $84.06), increasing direct ownership by 23% to 9,445 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/23/25 4:08:36 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Rivas Maria bought $82,130 worth of shares (1,000 units at $82.13) (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/19/25 4:18:51 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Kurzius Lawrence Erik bought $165,000 worth of shares (2,000 units at $82.50), increasing direct ownership by 35% to 7,777 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/17/25 5:06:19 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Leadership Updates

    Live Leadership Updates

    View All

    CooperCompanies Appoints Paul Keel to its Board of Directors

    SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board. "We are delighted to welcome Paul to our Board as a new Director," said Colleen Jay, Chair of the Board of CooperCompanies. "His experience as a CEO in the medical device sector, along with a successful track record of leading complex global operations, will be a significant asset as Cooper continues to execute its strategy and create long-term value for patient

    5/4/26 4:15:00 PM ET
    $COO
    $NVST
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments

    CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors

    SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today that the Company's Board of Directors (the "Board") has appointed Walter (Walt) M Rosebrough, Jr. as an independent director, effective as of January 3, 2026. In connection with this appointment, the Company also has entered into a cooperation agreement (the "Cooperation Agreement") with Browning West, LP. ("Browning West"). Mr. Rosebrough will join the Board's Corporate Governance & Nominating Committee. The Board has also agreed that, by the end of 2026, it shall provide due and serious consideration for Mr. Rosebrough to be appointed Chair of the Board. In

    12/23/25 8:00:00 AM ET
    $COO
    $STE
    $VREX
    Ophthalmic Goods
    Health Care
    Industrial Specialties
    Industrial Machinery/Components

    Browning West Delivers Letter to The Cooper Companies Board of Directors

    Cooper's Lack of Strategic Focus, Misaligned Incentives, and Inadequate Board Oversight Have Led to Meaningful Underperformance Current Corporate Structure Obscures Value of Both CooperVision and CooperSurgical; Refocus as a Pure Play Vision Care Company Under a Refreshed Board May Lead to More Than a Doubling of Cooper's Stock Price Urges Cooper's Board to Appoint Browning West's Highly Skilled Director Candidates Who Will Improve the Company's Operating Plans Including Capital Allocation, Overhaul Management Incentives, and Evaluate Strategic Alternatives for CooperSurgical LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Browning West, LP ("Browning West", "us", or "we"), an investment

    11/19/25 8:45:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/16/24 4:57:01 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G filed by The Cooper Companies Inc.

    SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/14/24 10:04:33 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/13/24 5:02:29 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Financials

    Live finance-specific insights

    View All

    CooperCompanies Announces Second Quarter 2026 Results

    SAN RAMON, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2026. Second quarter 2026 revenue of $1.082 billion, up 8%, or up 5% organically, from last year's second quarter.Second quarter 2026 GAAP diluted earnings per share (EPS) of $(0.40), down $0.84 from last year's second quarter driven by a litigation-related charge to resolve outstanding claims associated with a December 2023 voluntary product recall at CooperSurgical.Second quarter 2026 Non-GAAP diluted EPS of $1.21, up $0.25 or 26% from last year's second quarter. See "Reconciliation of

    6/4/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Release Date for Second Quarter 2026

    SAN RAMON, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today it will report second quarter 2026 financial results on Thursday, June 4, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at www.investor.coopercos.com About CooperCompanies CooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beauti

    4/30/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces First Quarter 2026 Results

    SAN RAMON, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2026. First quarter 2026 revenue of $1.024 billion, up 6%, or up 3% organically, from last year's first quarter.First quarter 2026 GAAP diluted earnings per share (EPS) of $0.66, up $0.14 or 27% from last year's first quarter.First quarter 2026 Non-GAAP diluted EPS of $1.10, up $0.18 or 20% from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. "We're pleased to report a strong start to the fiscal year, highlighted by product launches,

    3/5/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care